Evaluation of the attitudes of specialist and family physicians regarding rational drug selection.

North Clin Istanb

Department of Economical Assessments & Drug Supply Management, Turkish Medicines and Medical Devices Agency, Ministry of Health, Ankara, Turkey.

Published: September 2018

AI Article Synopsis

Article Abstract

Objective: Physicians' personal (P) drugs, which were ranked by priority, may show variations even for the same indication. We aimed to evaluate physicians' knowledge and attitudes regarding P-drug list preparation with respect to the rational use of medicine context.

Methods: A total of 1062 family physicians (FPs) and 562 specialist physicians (SPs) were interviewed and questioned about their knowledge and attitude regarding P-drug list preparation.

Results: Compared with SPs (64.9%), significantly more number of FPs (72.8%) prepared a P-drug list. Women were more likely to prepare the P-drug list in both groups; gender comparison showed that significantly more number of female FPs (75.9%) exhibited this attitude than female SPs (67.8%) (p=0.002). Among SPs, the trend for P-drug list preparation attitude decreased with increasing age (p=0.006), and significantly less number of senior physicians showed this attitude compared with junior physicians (p=0.007). The most common source of information referred to by FPs (78.9%) and SPs (74.3%) during P-drug list preparation was "pharmaceutical company activities." More than 80% of responders (80.9% of FPs and 83.6% of SPs) specified that a difference "exists" or "partially exists" between original and generic drugs. Approximately one in 10 physicians in both groups stated that they "rarely/never" consider their patients' "liver/kidney disease" during prescribing.

Conclusion: More prominently in male and senior physicians, the attitude of P-drug list preparation remained lower than expected. Moreover, it is remarkable that pharmaceutical company promotions are the most common source of information for drug selection. These findings disclose the need for the rational use of medicine dissemination interventions for all physicians focusing on more effective use of P-drug list.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323565PMC
http://dx.doi.org/10.14744/nci.2017.82788DOI Listing

Publication Analysis

Top Keywords

p-drug list
32
list preparation
16
physicians
8
family physicians
8
drug selection
8
p-drug
8
list
8
rational medicine
8
attitude p-drug
8
senior physicians
8

Similar Publications

Case-based Learning: Our Experience in Clinical Pharmacology Teaching.

J Pharm Bioallied Sci

January 2019

Department of Public Health, School of Medicine, Taylor's University, Kuala Lumpur, Malaysia.

Majority of junior doctors struggle to apply the knowledge of pharmacology to prescribing drugs. A paradigm shift in teaching of clinical pharmacology is the need of the hour in medical curriculum. One of the ways to enhance the teaching of clinical pharmacology is to develop and conduct case-based learning for MBBS students instead of didactic lecturing.

View Article and Find Full Text PDF

Evaluation of the attitudes of specialist and family physicians regarding rational drug selection.

North Clin Istanb

September 2018

Department of Economical Assessments & Drug Supply Management, Turkish Medicines and Medical Devices Agency, Ministry of Health, Ankara, Turkey.

Objective: Physicians' personal (P) drugs, which were ranked by priority, may show variations even for the same indication. We aimed to evaluate physicians' knowledge and attitudes regarding P-drug list preparation with respect to the rational use of medicine context.

Methods: A total of 1062 family physicians (FPs) and 562 specialist physicians (SPs) were interviewed and questioned about their knowledge and attitude regarding P-drug list preparation.

View Article and Find Full Text PDF

Identifying genes for bipolar mood disorders through classic genetics has proven difficult. Here, we present a comprehensive convergent approach that translationally integrates brain gene expression data from a relevant pharmacogenomic mouse model (involving treatments with a stimulant--methamphetamine, and a mood stabilizer--valproate), with human data (linkage loci from human genetic studies, changes in postmortem brains from patients), as a bayesian strategy of crossvalidating findings. Topping the list of candidate genes, we have DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of 32 kDa) located at 17q12, PENK (preproenkephalin) located at 8q12.

View Article and Find Full Text PDF

Choosing a drug from within a class.

Aust Fam Physician

June 2003

Department of Clinical Pharmacology, Royal Adelaide Hospital, University of Adelaide, South Australia.

Background: Having decided on a drug class, an individual drug needs to be chosen.

Objective: This article discusses the same four factors used in deciding the generic drug within a class as well as between different drug classes: efficacy, safety, suitability, and cost.

Discussion: The example of hypertension will be used to illustrate the choice of individual drugs within beta blockers and calcium channel blockers.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!